Patients with a PD-L1 tumor proportion score (TPS) ≥ 25% were more likely to have a MPR or PCR, but 58% of patients with a PD-L1 TPS <25% still had a MPR or PCR, suggesting PD-L1 was not a sensitive marker of response. The gene discussed is CD274; the disease is neoplasm.